Association of epirubicin, etoposide and cisplatin in gastric cancer. A phase II study

C. Barone, A. Cassano, A. Astone, E. Ricevuto, T. Fontana, M. R. Noviello, C. Garufi, F. Pacelli, A. Grieco

Research output: Contribution to journalArticlepeer-review


Cisplatin-based drug combinations are now currently investigated in an attempt to surpass the results obtainable by 5-FU alone or by 5-FU-containing regimens. We evaluated 29 patients with advanced and measurable gastric adenocarcinoma treated with etoposide, epirubicin and cisplatin. One patient had complete response (3±7%); 9 patients had partial response (31±17%); 5 patients (17±14%) were considered stable (S) and 14 (48±18%) were classified as progressive. The average survival time for the entire group was 11 months with 25% of the patients alive at 24 months. We feel that cisplatin-containing regimens are promising and deserve further investigations. To clearly explore the potential innovative role of these regimens randomized trials versus FAM or 5-FU alone are mandatory.

Original languageEnglish
Pages (from-to)353-355
Number of pages3
Issue number5
Publication statusPublished - 1991


  • Chemotherapy
  • Cisplatin
  • Epirubicin
  • Etoposide
  • Gastric cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Association of epirubicin, etoposide and cisplatin in gastric cancer. A phase II study'. Together they form a unique fingerprint.

Cite this